At3g58590 Antibody

What is the At3g58590 gene and why would researchers develop antibodies against its protein product?

At3g58590 encodes the XBAT35 protein, a RING E3 ligase involved in ubiquitin-mediated protein degradation in Arabidopsis thaliana. This gene undergoes alternative splicing generating two constitutively and ubiquitously expressed transcripts . The two splice variants result from an exon-skipping event that excludes a nuclear localization signal (NLS), determining the dual targeting of encoded isoforms - the NLS-containing isoform localizes to the nucleus and accumulates in speckles, while the isoform lacking the NLS localizes to the cytoplasm . Researchers develop antibodies against this protein to study:

• Expression patterns across tissues and developmental stages

• Subcellular localization of the different isoforms

• Protein-protein interactions

• Post-translational modifications

• Functional roles in ethylene-mediated signaling and plant development

• Substrate recognition and ubiquitination targets

How are antibodies against plant proteins like At3g58590 typically generated?

Generating antibodies against plant proteins like At3g58590 involves several critical steps:

• Antigen design and preparation:

  • Expression of recombinant full-length XBAT35 protein or specific fragments

  • Synthesis of unique peptides from each isoform (particularly important for distinguishing the NLS-containing versus NLS-lacking variants)

  • Consideration of protein solubility and native conformation

• Immunization and antibody production:

  • Selection of appropriate host animals (typically rabbits for polyclonal antibodies)

  • Implementation of suitable immunization protocols with proper adjuvants

  • Collection and purification of antisera

• Antibody validation:

  • Western blotting against recombinant protein and plant extracts

  • Testing in xbat35 knockout/RNAi lines as negative controls

  • Confirmation of specificity using XBAT35-overexpressing plants

• Purification strategies:

  • Affinity purification using immobilized antigen

  • Cross-adsorption against related proteins to minimize cross-reactivity with XBAT34

  • Isoform-specific antibody isolation when needed

What experimental techniques commonly employ At3g58590 antibodies?

At3g58590 antibodies can be utilized in multiple experimental techniques:

• Protein detection and quantification:

  • Western blotting to assess protein expression levels

  • Enzyme-linked immunosorbent assay (ELISA) for quantitative analysis

  • Immunohistochemistry to determine tissue-specific expression patterns

• Localization studies:

  • Immunofluorescence microscopy to visualize subcellular distribution (nuclear vs. cytoplasmic isoforms)

  • Subcellular fractionation followed by immunoblotting

  • Comparison with XBAT35-YFP fusion protein localization

• Interaction studies:

  • Co-immunoprecipitation to identify protein interaction partners

  • Chromatin immunoprecipitation (ChIP) if nuclear XBAT35 associates with chromatin

  • Pull-down assays to validate interactions with substrate candidates

• Functional analyses:

  • Analysis of protein levels during ethylene-mediated apical hook development

  • Immunoprecipitation followed by ubiquitination assays

  • Correlation of protein levels with phenotypic analyses in mutant and wild-type plants

How can I distinguish between the two splice variants of At3g58590 using antibodies?

Distinguishing between XBAT35 splice variants requires careful antibody design and experimental approaches:

• Isoform-specific antibody generation:

  • Target the nuclear localization signal (NLS) region present only in the nuclear isoform

  • Target the unique junction created by exon skipping in the cytoplasmic isoform

  • Design peptide antigens that specifically recognize each variant

• Validation strategies:

  • Express both recombinant isoforms separately as positive controls

  • Perform western blotting on nuclear and cytoplasmic fractions

  • Compare immunostaining patterns with the established localization of YFP-tagged isoforms

• Experimental approaches:

  • Combine subcellular fractionation with western blotting

  • Use fluorescence microscopy with isoform-specific antibodies

  • Perform quantitative analysis to determine isoform ratios

• Controls and considerations:

  • Include splice-blocking experiments to alter isoform ratios

  • Use epitope-tagged constructs expressing individual isoforms

  • Consider post-translational modifications that might affect epitope recognition

What are the challenges in detecting native At3g58590 protein in plant tissues?

Detecting native XBAT35 protein presents several significant challenges:

• Low abundance issues:

  • E3 ligases typically occur at low concentrations in cells

  • Transient expression during specific developmental windows

  • Variable expression across different tissues and conditions

• Protein stability considerations:

  • E3 ligases often have rapid turnover rates

  • Self-ubiquitination may lead to degradation during extraction

  • Proteasome inhibitors (MG132) may be required during sample preparation

• Isoform complexity:

  • Distinguishing between similarly sized splice variants

  • Nuclear isoform may be present in lower abundance

  • Different extraction efficiencies for nuclear versus cytoplasmic proteins

• Technical limitations:

  • Need for highly sensitive detection methods

  • Background signals in plant extracts

  • Cross-reactivity with related proteins like XBAT34

• Extraction optimization:

  • Specialized buffers for membrane-associated E3 ligases

  • Nuclear extraction protocols for the NLS-containing isoform

  • Prevention of protein degradation during sample processing

How can At3g58590 antibodies be used to study the protein's role in ethylene-mediated development?

XBAT35 antibodies can effectively investigate the protein's role in ethylene-mediated development through:

• Developmental expression analysis:

  • Track protein levels during apical hook development stages

  • Compare protein abundance between ethylene-treated and control seedlings

  • Correlate protein levels with the degree of hook curvature phenotypes observed in xbat35 mutants

• Subcellular dynamics:

  • Monitor changes in nuclear versus cytoplasmic distribution upon ethylene treatment

  • Analyze possible post-translational modifications in response to ethylene

  • Determine if isoform ratios change during ethylene-mediated development

• Protein interaction studies:

  • Identify ethylene-dependent interaction partners through co-immunoprecipitation

  • Validate interactions with the photosystem proteins identified as putative XBAT35 interacting partners

  • Investigate changes in the XBAT35 interactome during apical hook development

• Substrate identification:

  • Immunoprecipitate XBAT35 from ethylene-treated seedlings

  • Identify and validate ubiquitination targets

  • Analyze substrate stability in wild-type versus xbat35 loss-of-function lines

• Complementation analysis:

  • Use antibodies to verify protein expression in complementation experiments

  • Compare functionality of both XBAT35 isoforms in rescuing ethylene-related phenotypes

  • Correlate protein levels with phenotypic restoration

What methods can be used to validate the specificity of newly developed At3g58590 antibodies?

Validating At3g58590 antibody specificity requires multiple complementary approaches:

• Genetic validation:

  • Test on wild-type plants versus xbat35 knockout/RNAi lines

  • Examine signal in XBAT35-overexpressing plants

  • Compare reactivity in different genetic backgrounds

• Biochemical validation:

  • Pre-absorption with immunizing antigen to eliminate specific signal

  • Competition assays with purified recombinant XBAT35 protein

  • Cross-reactivity testing with related proteins, especially XBAT34

• Immunoprecipitation validation:

  • Mass spectrometry confirmation of immunoprecipitated proteins

  • Reciprocal co-immunoprecipitation with tagged versions

  • Size verification of immunoprecipitated proteins

• Localization confirmation:

  • Compare immunofluorescence patterns with YFP-fusion protein localization

  • Verify nuclear speckle localization for the NLS-containing isoform

  • Confirm cytoplasmic distribution for the NLS-lacking variant

• Multiple antibody approach:

  • Develop antibodies against different regions of XBAT35

  • Compare reactivity patterns across different antibody preparations

  • Use epitope-tagged versions as additional controls

What is the optimal protein extraction method for detecting At3g58590 in plant tissues?

Optimal extraction of XBAT35 requires consideration of its properties as an E3 ligase and its dual subcellular localization:

• General extraction buffer components:

  • Tris-HCl buffer (pH 7.5-8.0) with 150-250 mM NaCl

  • Detergents: 0.5-1% Triton X-100 or 0.5% NP-40

  • Protease inhibitor cocktail (PMSF, leupeptin, aprotinin, pepstatin A)

  • DTT or β-mercaptoethanol (1-5 mM) to maintain reducing conditions

  • EDTA (1-5 mM) to chelate metal ions

• E3 ligase-specific considerations:

  • Include proteasome inhibitors (10-50 μM MG132)

  • Add deubiquitinating enzyme inhibitors (5-10 mM N-ethylmaleimide)

  • Consider quick extraction at cold temperatures to preserve unstable proteins

• Isoform-specific extraction:

  • For nuclear isoform: perform nuclear extraction with specialized buffers

  • For cytoplasmic isoform: use gentler extraction conditions

  • Consider sequential extraction for comparative analysis

• Tissue-specific optimization:

  • For seedlings: rapid freezing in liquid nitrogen followed by grinding

  • For specific tissues: adapt grinding methods and buffer compositions

  • Consider developmental stage given XBAT35's role in hook development

• Processing considerations:

  • Process samples quickly to prevent degradation

  • Clarify extracts properly (16,000-20,000 × g centrifugation)

  • Quantify protein accurately for consistent loading

How can I optimize western blot conditions for detecting At3g58590 protein?

Optimizing western blot conditions for XBAT35 detection:

• Sample preparation:

  • Add sample buffer with sufficient SDS (2%) and reducing agent

  • Heat samples at 70-95°C for 5-10 minutes (optimize to prevent aggregation)

  • Load adequate protein amount (30-100 μg total protein)

• Gel and transfer parameters:

  • Use 8-10% SDS-PAGE for optimal resolution of XBAT35 isoforms

  • Consider gradient gels (4-15%) if analyzing both free and ubiquitin-conjugated forms

  • Transfer to PVDF membranes at 100V for 1 hour or 30V overnight at 4°C

  • Use 10-20% methanol in transfer buffer for efficient protein transfer

• Antibody conditions:

  • Blocking: 5% non-fat dry milk or 3-5% BSA in TBST (1-2 hours at room temperature)

  • Primary antibody: test dilutions from 1:500 to 1:5000, incubate overnight at 4°C

  • Washing: 4-6 times with TBST, 5-10 minutes each

  • Secondary antibody: 1:5000 to 1:10000, 1-2 hours at room temperature

  • Enhanced chemiluminescence with appropriate exposure times

• Controls and standards:

  • Include recombinant XBAT35 protein as positive control

  • Use extracts from xbat35 mutant plants as negative control

  • Include molecular weight markers to confirm expected size

• Troubleshooting:

  • For weak signals: extend exposure time or use signal enhancement systems

  • For high background: increase washing steps or adjust blocking conditions

  • For multiple bands: analyze with isoform-specific antibodies

What approaches are effective for immunoprecipitating At3g58590 to identify its interaction partners?

Effective immunoprecipitation of XBAT35 for interaction partner identification:

• Extraction condition optimization:

  • Use buffers containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5-1% NP-40

  • Include proteasome inhibitors to stabilize ubiquitinated substrates

  • Add phosphatase inhibitors to preserve phosphorylation-dependent interactions

  • Consider crosslinking with formaldehyde (0.5-1%) for transient interactions

• IP protocol refinement:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Incubate with XBAT35 antibody (2-5 μg per mg of protein) overnight at 4°C

  • Use proper negative controls (pre-immune serum, IgG, xbat35 mutant extracts)

  • Wash extensively with decreasing detergent concentrations

• E3 ligase-specific strategies:

  • Analyze samples in the presence and absence of proteasome inhibitors

  • Consider tandem ubiquitin-binding entities (TUBEs) to enrich ubiquitinated proteins

  • Use in vitro ubiquitination assays to validate potential substrates

  • Test interactions with the photosystem proteins identified as putative XBAT35 partners

• Isoform-specific considerations:

  • Use isoform-specific antibodies for differential interactome analysis

  • Compare nuclear versus cytoplasmic fraction immunoprecipitations

  • Consider the impact of the NLS on protein-protein interactions

• Analysis methods:

  • Mass spectrometry identification of co-immunoprecipitated proteins

  • Western blot validation of specific interaction candidates

  • Consider label-free quantification to compare different conditions

How can quantitative approaches be used to measure At3g58590 protein levels accurately?

Quantitative measurement of XBAT35 protein levels requires:

• Western blot quantification:

  • Use fluorescent secondary antibodies for wider linear range

  • Include standard curves with recombinant XBAT35 protein

  • Normalize to appropriate loading controls (actin, tubulin, GAPDH)

  • Analyze with software like ImageJ for densitometry

  • Perform technical replicates (minimum 3) for statistical robustness

• ELISA development:

  • Generate sandwich ELISA using two antibodies targeting different epitopes

  • Develop standard curves with purified recombinant protein

  • Optimize blocking and washing conditions for plant samples

  • Include appropriate negative controls (xbat35 mutant/RNAi extracts)

• Mass spectrometry approaches:

  • Develop selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) assays

  • Use isotope-labeled peptide standards for absolute quantification

  • Select unique peptides for each XBAT35 isoform

  • Create a targeted method focusing on unique tryptic peptides

• Data analysis and statistics:

  • Apply appropriate statistical tests (t-test, ANOVA) based on experimental design

  • Calculate variability (CV%) across technical and biological replicates

  • Report confidence intervals for measurements

  • Correlate protein levels with transcript abundance data

• Isoform ratio determination:

  • Use isoform-specific antibodies or peptides

  • Develop targeted assays that can distinguish splice variants

  • Compare ratios across different tissues and conditions

Why might my At3g58590 antibody show inconsistent results between different tissues?

Inconsistent XBAT35 antibody results across tissues can stem from several factors:

• Differential expression patterns:

  • XBAT35, despite being ubiquitously expressed , may have tissue-specific abundance

  • Developmental regulation may affect expression levels across tissues

  • The ratio of nuclear to cytoplasmic isoforms might vary between tissues

• Extraction efficiency differences:

  • Nuclear proteins extract with different efficiencies from various tissues

  • Cell wall composition affects protein extraction yield

  • Presence of secondary metabolites in specific tissues may interfere with extraction

• Post-translational modifications:

  • Tissue-specific phosphorylation or ubiquitination might mask antibody epitopes

  • Differential protein processing may generate tissue-specific fragments

  • Protein complex formation may sequester epitopes in certain tissues

• Technical considerations:

  • Protein degradation rates vary between tissues

  • Matrix effects from tissue-specific components can affect antibody binding

  • Inconsistent protein transfer efficiency during western blotting

• Solutions:

  • Optimize extraction protocols for each tissue type

  • Include appropriate extraction controls

  • Use subcellular fractionation followed by western blotting

  • Normalize loading based on total protein rather than equal amounts

What are common false positives/negatives in At3g58590 antibody experiments and how can they be addressed?

Common issues in XBAT35 antibody experiments include:

False positives:

• Cross-reactivity with related proteins:

  • XBAT34 has overlapping expression patterns with XBAT35

  • Other RING E3 ligases may share structural similarities

  • Solution: Validate using xbat35 knockout/RNAi lines and peptide competition assays

• Non-specific binding:

  • Plant extracts contain abundant proteins that may bind non-specifically

  • Secondary antibody cross-reactivity with plant proteins

  • Solution: Optimize blocking conditions and include appropriate controls

• Degradation products:

  • E3 ligases are often unstable and produce fragments

  • Solution: Include protease inhibitors and process samples quickly

False negatives:

• Epitope masking:

  • Post-translational modifications may block antibody recognition

  • Protein-protein interactions might hide epitopes

  • Solution: Try different extraction conditions and denaturation methods

• Low abundance:

  • XBAT35 may be present at levels below detection limits

  • Solution: Enrich using subcellular fractionation or immunoprecipitation

• Rapid protein turnover:

  • E3 ligases often have short half-lives

  • Solution: Treat plants with proteasome inhibitors before extraction

• Verification strategies:

  • Use multiple antibodies targeting different epitopes

  • Include positive controls (recombinant protein, overexpression lines)

  • Implement proper negative controls (knockout/RNAi lines)

  • Combine protein and transcript analysis for comprehensive validation

How can I detect changes in At3g58590 isoform ratios during plant development or stress responses?

Detecting changes in XBAT35 isoform ratios requires:

• Isoform-specific detection methods:

  • Develop antibodies targeting unique regions of each isoform

  • Use RT-PCR primers spanning the alternatively spliced exon

  • Design quantitative PCR assays for splice junction-specific amplification

• Protein-based approaches:

  • Western blotting with antibodies that can distinguish isoforms

  • Subcellular fractionation to separate nuclear and cytoplasmic proteins

  • Quantitative proteomics using isoform-specific peptides

• Experimental design considerations:

  • Establish developmental time courses focusing on ethylene-regulated processes

  • Compare tissue-specific expression patterns

  • Analyze stress responses (particularly ethylene treatment)

  • Include appropriate controls and biological replicates

• Data analysis:

  • Calculate isoform ratios rather than absolute levels

  • Perform statistical analysis to determine significant changes

  • Correlate protein isoform ratios with splicing changes at the RNA level

  • Use appropriate normalization for each subcellular compartment

• Validation strategies:

  • Create isoform-specific overexpression lines as positive controls

  • Use splice site mutants to alter isoform ratios

  • Implement multiple detection methods for cross-validation

What statistical approaches are appropriate for quantifying At3g58590 protein level changes?

Appropriate statistical approaches for XBAT35 protein quantification:

• Basic statistical tests:

  • Student's t-test for comparing two conditions

  • ANOVA with appropriate post-hoc tests for multiple condition comparisons

  • Non-parametric tests (Mann-Whitney, Kruskal-Wallis) for non-normally distributed data

• Experimental design considerations:

  • Minimum of 3-4 biological replicates per condition

  • Technical replicates for western blotting or ELISA (minimum 3)

  • Proper randomization and blinding where applicable

  • Power analysis to determine appropriate sample size

• Normalization strategies:

  • Housekeeping proteins (actin, tubulin)

  • Total protein normalization (stain-free technology)

  • For tissue comparisons, consider tissue-specific reference proteins

• Advanced approaches:

  • Regression analysis for dose-response or time-course experiments

  • Mixed-effects models for complex experimental designs

  • Bayesian statistics for situations with limited replicates

• Data presentation:

  • Include error bars (standard deviation or standard error)

  • Report exact p-values and confidence intervals

  • Present both raw data and normalized results

  • Use consistent scales when comparing across experiments

How can At3g58590 antibodies be used to study the role of this protein in ethylene-mediated apical hook development?

Studying XBAT35's role in ethylene-mediated apical hook development with antibodies:

• Developmental expression analysis:

  • Track XBAT35 protein levels during hook formation, maintenance, and opening phases

  • Compare protein abundance between ethylene-treated and control seedlings

  • Correlate protein levels with the hypersensitivity to ethylene observed in xbat35 loss-of-function lines

• Isoform-specific contributions:

  • Analyze the relative abundance of nuclear versus cytoplasmic isoforms during hook development

  • Use isoform-specific antibodies to determine their individual contributions

  • Validate the finding that both XBAT35 isoforms function in ethylene control of apical hook curvature

• Protein interaction dynamics:

  • Identify ethylene-regulated interaction partners through co-immunoprecipitation

  • Investigate how ethylene treatment affects XBAT35 interactions

  • Validate interactions with the photosystem proteins identified as putative partners

• Protein turnover analysis:

  • Assess XBAT35 stability under different ethylene concentrations

  • Determine if XBAT35 itself is regulated post-translationally during hook development

  • Compare degradation rates of putative XBAT35 substrates in wild-type versus xbat35 plants

• Spatial analysis:

  • Perform immunohistochemistry to determine cell-specific expression in the apical hook

  • Compare protein distribution between the concave and convex sides of the hook

  • Correlate with asymmetric growth patterns during hook development

How can chromatin immunoprecipitation be used with At3g58590 antibodies to study the nuclear isoform?

Applying ChIP with XBAT35 antibodies to study the nuclear isoform:

• ChIP protocol optimization:

  • Use antibodies specific to the NLS-containing nuclear isoform

  • Implement dual crosslinking approaches (formaldehyde plus protein-specific crosslinkers)

  • Optimize sonication conditions for proper chromatin fragmentation (200-500 bp)

  • Include appropriate controls (IgG, input, xbat35 mutant)

• Target gene identification:

  • Focus on ethylene-responsive genes given XBAT35's role in ethylene signaling

  • Compare ChIP-seq profiles with transcriptomic data from xbat35 mutants

  • Look for enrichment near genes encoding known XBAT35 interacting partners

• Data analysis approaches:

  • Peak calling using appropriate algorithms (MACS2)

  • Motif analysis to identify common sequence elements

  • Integration with other genomic datasets (DNase-seq, ATAC-seq)

  • Pathway enrichment analysis of target genes

• Functional considerations:

  • Remember that XBAT35 is an E3 ligase, not a transcription factor

  • Consider indirect DNA association through interaction with chromatin proteins

  • Investigate potential ubiquitination of histones or transcription factors

  • Examine the nuclear speckle localization in relation to transcriptionally active regions

• Validation strategies:

  • ChIP-qPCR validation of selected targets

  • Reporter gene assays to confirm functional relevance

  • Create targeted mutations in binding sites to assess functional impacts

How can mass spectrometry be combined with At3g58590 antibodies to identify ubiquitination targets?

Combining mass spectrometry with XBAT35 antibodies to identify ubiquitination targets:

• Sample preparation approaches:

  • Treat plants with proteasome inhibitors to stabilize ubiquitinated proteins

  • Include deubiquitinase inhibitors in extraction buffers

  • Perform XBAT35 immunoprecipitation under native conditions

  • Consider TUBE (tandem ubiquitin-binding entity) purification in parallel

• MS workflow options:

  • Standard IP-MS to identify XBAT35-associated proteins

  • Ubiquitin remnant profiling to identify specific ubiquitination sites

  • Quantitative proteomics comparing wild-type vs. xbat35 mutant/RNAi lines

  • SILAC or TMT labeling for precise quantification of changes

• Data analysis strategies:

  • Filter for proteins enriched in wild-type compared to knockout controls

  • Focus on proteins with K-GG (ubiquitin remnant) modifications

  • Cross-reference with yeast two-hybrid results that identified five candidate substrates

  • Apply pathway analysis to identify functional clusters

• Validation experiments:

  • In vitro ubiquitination assays with recombinant XBAT35 and candidate substrates

  • Co-IP and western blot analysis to confirm interactions

  • Analyze substrate stability in wild-type versus xbat35 mutant backgrounds

  • Test the photosystem proteins and unknown protein identified as putative XBAT35 interacting partners

• Isoform-specific analysis:

  • Compare targets between nuclear and cytoplasmic isoforms

  • Perform parallel IP-MS with isoform-specific antibodies

  • Correlate with subcellular localization data

How can At3g58590 antibodies be integrated with emerging plant biotechnology approaches?

Integrating XBAT35 antibodies with emerging biotechnology approaches:

• CRISPR/Cas9 applications:

  • Use antibodies to validate CRISPR-edited plants

  • Create epitope-tagged endogenous XBAT35 using CRISPR knock-in

  • Generate isoform-specific knockouts through targeted editing of the alternatively spliced exon

  • Validate editing outcomes with isoform-specific antibodies

• Proximity labeling approaches:

  • Fuse XBAT35 to BioID or TurboID for in vivo proximity labeling

  • Use XBAT35 antibodies to immunoprecipitate the fusion protein

  • Compare proximity labeling results with traditional co-IP to identify transient interactions

  • Implement isoform-specific proximity labeling to distinguish nuclear vs. cytoplasmic interactomes

• Single-cell applications:

  • Develop protocols for antibody-based detection in plant protoplasts

  • Combine with fluorescence-activated cell sorting (FACS)

  • Implement spatial transcriptomics with antibody staining

  • Correlate protein expression with single-cell RNA-seq data

• Synthetic biology approaches:

  • Use antibodies to validate synthetic XBAT35 variants

  • Create engineered ubiquitination circuits with modified specificity

  • Develop optogenetic control of XBAT35 function

  • Monitor protein behavior in synthetic systems

• Interspecies comparisons:

  • Cross-reactivity testing with XBAT35 homologs in other plant species

  • Evolutionary analysis of E3 ligase function across plant lineages

  • Development of broadly reactive antibodies for comparative studies

  • Assessment of conservation in splicing-dependent targeting mechanisms